What was the return on investment of the COVID-19 vaccination campaign in New York City? YaleSPH NewYork USA ROI COVID19 SARSCoV2 Vaccination VaccinationCampaign
By Tarun Sai LomteNov 24 2022Reviewed by Aimee Molineux A recent study published in JAMA Network Open estimated the return on investment of New York City’s coronavirus disease 2019 vaccination campaign.
A study reported that NYC Vaccine for All Campaign decreased disease burden considerably. This health success required significant financial investment for vaccine acquisition and delivery, vaccination promotion events, and addressing vaccine skepticism. Understanding ROI would offer valuable insights into vaccination campaigns and ending the COVID-19 pandemic.
Indirect health outcomes were the losses of workdays and production incurred from sickness and adverse reactions to COVID-19 vaccines. The total costs for the final investment value were calculated by calibrating an agent-based simulation model for confirmed and probable COVID-19 cases in the pandemic and a counterfactual scenario without vaccination in NYC, accounting for COVID-19 characteristics and SARS-CoV-2 variant timelines.
The authors estimated that vaccination precluded $27.96 billion of additional healthcare costs that would have been incurred without vaccination. The COVID-19 pandemic resulted in 92,280 PYLL in NYC, with a VSL loss of $7.7 billion. The mean PYLL stood at 6.06 per individual. They noted that the total PYLL, without vaccination, would have been significantly more , leading to a VSL loss of $33.93 billion. Vaccination averted 315,724 PYLL and generated net VSL savings of $26.27 billion.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
The negative impact of COVID-19 on working memory revealed using a rapid online quizAlthough coronavirus disease 2019 (COVID-19) affects the respiratory system, it can also have neurological consequences leading to cognitive deficits such as memory problems. The aim of our study was to assess the impact of COVID-19 on working memory function. We developed and implemented an online anonymous survey with a working memory quiz incorporating aspects of gamification to engage participants. 5428 participants successfully completed the survey and memory quiz between 8th December 2020 and 5th July 2021 (68.6% non-COVID-19 and 31.4% COVID-19). Most participants (93.3%) completed the survey and memory quiz relatively rapidly (mean time of 8.84 minutes). Categorical regression was used to assess the contribution of COVID status, age, time post-COVID (number of months elapsed since having had COVID), symptoms, ongoing symptoms and gender, followed by non-parametric statistics. A principal component analysis explored the relationship between subjective ratings and objective memory scores. The objective memory scores were significantly correlated with participants’ own assessment of their cognitive function. The factors significantly affecting memory scores were COVID status, age, time post-COVID and ongoing symptoms. Our main finding was a significant reduction in memory scores in all COVID groups (self-reported, positive-tested and hospitalized) compared to the non-COVID group. Memory scores for all COVID groups combined were significantly reduced compared to the non-COVID group in every age category 25 years and over, but not for the youngest age category (18–24 years old). We found that memory scores gradually increased over a period of 17 months post-COVID-19. However, those with ongoing COVID-19 symptoms continued to show a reduction in memory scores. Our findings demonstrate that COVID-19 negatively impacts working memory function, but only in adults aged 25 years and over. Moreover, our results suggest that working memory deficits with COVID-19 can recov
Read more »
Frontiers | Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patientsEctonucleotidases modulate inflammatory responses by balancing extracellular ATP and adenosine (ADO) and might be involved in COVID-19 immunopathogenesis. Here, we explored the contribution of extracellular nucleotides metabolism to COVID-19 severity in mild and severe cases of the disease. We verified that the gene expression of ectonucleotidases is reduced in the whole blood of patients with COVID-19 and is negatively correlated to CRP plasma levels, an inflammatory marker of disease severity. In line with these findings, COVID-19 patients present higher ATP levels in plasma and reduced levels of ADO when compared to healthy controls. Cell type-specific analysis revealed higher frequencies of CD39+ T cells in severely ill patients, while CD4+ and CD8+ expressing CD73 are reduced in this same group. The frequency of B cells CD39+CD73+ is also decreased during acute COVID-19. Interestingly, B cells from COVID-19 patients showed a reduced capacity to hydrolyze ATP into ADP and ADO. Furthermore, impaired expression of ADO receptors and a compromised activation of its signaling pathway is observed in COVID-19 patients. The presence of ADO in vitro, however, suppressed inflammatory responses triggered in patients’ cells. In summary, our findings support the idea that alterations in the metabolism of extracellular purines contribute to immune dysregulation during COVID-19, possibly favoring disease severity, and suggest that ADO may be a therapeutic approach for the disease.
Read more »
Covid warning issued for age group as long-term sign could impact life every dayA new study has revealed that Covid-19 can cause short-term memory loss.
Read more »
New York sewer rats are easily infected by SARS-CoV-2, according to new studyNew York sewer rats are easily infected by SARS-CoV-2, according to new study biorxivpreprint Mizzou NewYork USA Rats Infection SARSCoV2 Variant COVID19
Read more »
The Walking Dead's Maggie and Negan return in first teaser for Dead City spinoffThe pair are facing new threats in New York.
Read more »